322 related articles for article (PubMed ID: 22040163)
1. Receptor tyrosine kinases: from biology to pathology.
Choura M; Rebaï A
J Recept Signal Transduct Res; 2011 Dec; 31(6):387-94. PubMed ID: 22040163
[TBL] [Abstract][Full Text] [Related]
2. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
4. KIDs rule: regulatory phosphorylation of RTKs.
Locascio LE; Donoghue DJ
Trends Biochem Sci; 2013 Feb; 38(2):75-84. PubMed ID: 23312584
[TBL] [Abstract][Full Text] [Related]
5. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
6. Activation of phosphatidylinositol 3-kinase is necessary for differentiation of FDC-P1 cells following stimulation of type III receptor tyrosine kinases.
Kubota Y; Angelotti T; Niederfellner G; Herbst R; Ullrich A
Cell Growth Differ; 1998 Mar; 9(3):247-56. PubMed ID: 9543391
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinases as targets for cancer therapy.
Krause DS; Van Etten RA
N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887
[No Abstract] [Full Text] [Related]
8. Activation of receptor protein-tyrosine kinases from the cytoplasmic compartment.
Yamanashi Y; Tezuka T; Yokoyama K
J Biochem; 2012 Apr; 151(4):353-9. PubMed ID: 22343747
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinases and their activation in melanoma.
Easty DJ; Gray SG; O'Byrne KJ; O'Donnell D; Bennett DC
Pigment Cell Melanoma Res; 2011 Jun; 24(3):446-61. PubMed ID: 21320293
[TBL] [Abstract][Full Text] [Related]
10. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
Tolmachev V; Stone-Elander S; Orlova A
Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
[TBL] [Abstract][Full Text] [Related]
11. Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains.
Grassot J; Gouy M; Perrière G; Mouchiroud G
Mol Biol Evol; 2006 Jun; 23(6):1232-41. PubMed ID: 16551648
[TBL] [Abstract][Full Text] [Related]
12. Deceiving appearances: signaling by "dead" and "fractured" receptor protein-tyrosine kinases.
Kroiher M; Miller MA; Steele RE
Bioessays; 2001 Jan; 23(1):69-76. PubMed ID: 11135311
[TBL] [Abstract][Full Text] [Related]
13. Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies.
Correll PH; Paulson RF; Wei X
Gene; 2006 Jun; 374():26-38. PubMed ID: 16524673
[TBL] [Abstract][Full Text] [Related]
14. Coupling receptor tyrosine kinases to Rho GTPases--GEFs what's the link.
Schiller MR
Cell Signal; 2006 Nov; 18(11):1834-43. PubMed ID: 16725310
[TBL] [Abstract][Full Text] [Related]
15. Revelations of the RYK receptor.
Halford MM; Stacker SA
Bioessays; 2001 Jan; 23(1):34-45. PubMed ID: 11135307
[TBL] [Abstract][Full Text] [Related]
16. Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors.
Büttner A; Cottin T; Xu J; Tzagkaroulaki L; Giannis A
Bioorg Med Chem; 2010 May; 18(10):3387-402. PubMed ID: 20456957
[TBL] [Abstract][Full Text] [Related]
17. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3).
Davis TL; Walker JR; Loppnau P; Butler-Cole C; Allali-Hassani A; Dhe-Paganon S
Structure; 2008 Jun; 16(6):873-84. PubMed ID: 18547520
[TBL] [Abstract][Full Text] [Related]
18. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases.
Natarajan K; Berk BC
Methods Mol Biol; 2006; 332():51-77. PubMed ID: 16878685
[TBL] [Abstract][Full Text] [Related]
20. All Good Things Must End: Termination of Receptor Tyrosine Kinase Signal.
Margiotta A
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
